Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden flag Sweden · Delayed Price · Currency is SEK
10.32
+0.41 (4.14%)
At close: Feb 5, 2026

Xbrane Biopharma AB Cash Flow Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
100.52-266.22-388.17-172.51-188.38-226.03
Depreciation & Amortization
9.4224.2121.4316.5812.225.77
Other Amortization
-----0.79
Stock-Based Compensation
-----1.29
Other Operating Activities
-258.7567.22145.36-7.25-5.04-1.61
Change in Accounts Receivable
154.07-4.56-85.131.7-61.09-51.33
Change in Inventory
11.52-166-56.6-50.26--
Change in Accounts Payable
-278.49212.8222.57---
Change in Other Net Operating Assets
---17.8322.6732.7
Operating Cash Flow
-89.22-133.73-406.68-193.92-219.61-238.41
Capital Expenditures
-109.96-0.5-6.79-11.62-27.68-3.86
Sale (Purchase) of Intangibles
-51.75-51.75-9.98-48.51-49.67-
Other Investing Activities
102.5-----
Investing Cash Flow
-59.21-52.25-16.77-60.13-77.35-3.86
Long-Term Debt Issued
-70225---
Long-Term Debt Repaid
--126.14-34.74-8.34-7.27-3.14
Total Debt Repaid
-51.03-126.14-34.74-8.34-7.27-3.14
Net Debt Issued (Repaid)
-11.03-56.14190.26-8.34-7.27-3.14
Issuance of Common Stock
240337.24120.02170.55380.87346.45
Other Financing Activities
-14.04-37.48-11.58-13.35-24.23-20.58
Financing Cash Flow
214.93243.62298.7148.86349.37322.72
Foreign Exchange Rate Adjustments
-4.010.84-4.494.051.39-1.52
Miscellaneous Cash Flow Adjustments
0.480.440.64-0.05-1.76-
Net Cash Flow
62.9758.93-128.59-101.1952.0478.94
Free Cash Flow
-199.18-134.23-413.47-205.53-247.29-242.26
Free Cash Flow Margin
-76.70%-67.55%-173.20%-356.72%-2309.16%-
Free Cash Flow Per Share
-10.75-13.64-1800.48-1004.76-1310.16-1671.85
Cash Interest Paid
17.6517.657.582.592.640.69
Levered Free Cash Flow
-219.3-67-244-169.78-279.72-153.39
Unlevered Free Cash Flow
-204.16-45.98-232.43-168.17-278.07-152.96
Change in Working Capital
-112.942.27-119.16-30.73-38.42-18.63
Source: S&P Global Market Intelligence. Standard template. Financial Sources.